about
The wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disordersThe current status of therapeutic HPV vaccineEngulfing tumors with synthetic extracellular matrices for cancer immunotherapyIL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.Cancer gene therapy: hard lessons and new courses.Improving vaccine performance with adjuvants.Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.The development of immunotherapies for non-small cell lung cancer.The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyImmunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Parvovirus vectors for cancer gene therapy.Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients.General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines.Cytokines as adjuvants for avian vaccines.Transloading of tumor antigen-derived peptides into antigen-presenting cellsActivation of preexisting T cell clones by targeted interleukin 2 therapy.Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanismsPhase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.Increased anti-tumor effect by a combination of HSV thymidine kinase suicide gene therapy and interferon-gamma/GM-CSF cytokine gene therapy in CT26 tumor model.Virus-like particle vaccines and adjuvants: the HPV paradigm.The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.Short and highly efficient synthetic promoters for melanoma-specific gene expression.Growth inhibition of mammalian cells by eosinophil cationic protein.The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity.Future therapies for the treatment of bladder neoplasms.The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer.Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.Selected anti-tumor vaccines merit a place in multimodal tumor therapies.
P2860
Q26775973-FC80707A-36A5-49DC-9728-A176AE0E5AC7Q28302676-29C6C7B1-469F-448D-BE8D-B7A5212EB1B2Q28749647-FBE8A00C-86AB-4992-9D0D-A1D8AC85C7F8Q33670036-AC418716-E9E6-4B5F-8070-3B50375BCC40Q33840974-FBF0F95A-79F7-45D0-BE56-957260F70AE2Q33956247-39DC2CA3-90BC-4E5E-A3D1-F309C0DF0737Q34467878-EB6FC228-04A0-4C5E-B141-4D170E3596DFQ34560660-4EE9A33B-F613-4E1C-A41F-02B1211BC8B9Q35047632-BCB6254A-C3B2-47B9-B45E-52D70BD2A988Q35119800-0CD1D8DF-6989-4235-B55C-DBB69FAF3035Q35142329-9A1F3AB1-83FD-4215-8514-B3C9872E633BQ35609780-42FCA3EF-7790-443B-AA25-7104F770D04BQ35787792-413C4F78-E742-40C3-ACBA-0E9C2E761070Q35947735-A356B34A-A5BF-4CB6-B1AE-1F20FBAE32A2Q35953768-E3C31DD9-F581-4EDC-906B-7388D66B7716Q36084026-DBC438CC-44B6-415D-B6B6-63B792A144FAQ36219989-6C75D0B4-2D18-4875-AB2E-4248E3CD16CBQ36292705-D3FBB52B-B1F4-4D71-9C15-E5003F906DC3Q36366108-CFF7C8BB-2449-48C8-A9A6-C414133B8383Q36366130-441BB8B7-5EC9-4CE7-8838-8B62868BB5E0Q36585688-AF84A283-F906-4111-9291-A80CA3179538Q36621492-7552AB94-B321-4AF2-A697-009B41D50EE8Q37247348-3BED2DE7-C2BF-4F77-B546-F818BAC2E663Q37362175-B7BD889C-4CBE-46D0-AF0D-AF8D4E3FA522Q37425821-ACD95027-194D-41B9-ABED-D843BA57758CQ37608311-54D0EC82-5216-4F93-B414-DB3E482FCF60Q37937045-3D599CE9-EAD1-4B63-A830-DCF84AB28AA2Q38187480-AB71828E-C697-439B-9F61-9F1D7F621C54Q39235364-AAF1375E-6BBE-47E0-9F9F-2D150B2D18C4Q39337108-D5AA5A15-9C10-43B6-8D71-EC3379B7AAA7Q39458469-7C9B4D7E-5786-46F0-928C-127AB05091F1Q40197046-95ECE590-C648-423D-87C3-71B37F1FA48AQ40476867-0192BDD7-0FB8-454D-8B68-BD20C86AAE25Q40758000-0BEF7BB7-ED4A-476D-A2EB-DE1DDB4B7E81Q40810927-786DB317-0813-405D-800A-A0B8315C573FQ40874415-86F3E3AD-C7F8-4AA6-978F-61E40B5DDCE7Q40883449-EDCD8B95-96CA-4E43-BE67-14790A33AA18Q41095702-2C504462-036A-4771-8D49-E64B67E09C40Q42261548-67ACD2BC-988A-4AB9-8D4A-DB0A2232B311Q42448191-359A5AFD-EF31-4138-9485-C048CBDAF4CA
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Paracrine cytokine adjuvants in cancer immunotherapy.
@en
type
label
Paracrine cytokine adjuvants in cancer immunotherapy.
@en
prefLabel
Paracrine cytokine adjuvants in cancer immunotherapy.
@en
P1476
Paracrine cytokine adjuvants in cancer immunotherapy.
@en
P2093
Pardoll DM
P304
P356
10.1146/ANNUREV.IY.13.040195.002151
P577
1995-01-01T00:00:00Z